CDO1 and CELF4 methylation assay as the dominant predictor of endometrial cancer: A cohort analysis across pre- and post-menopausal cohorts

Key Points

• Methylation assay serves as a dominant predictor for endometrial cancer diagnosis, aiding in early detection.
• The analysis includes both pre-menopausal and post-menopausal cohorts, providing comprehensive insights.
• Cohort analysis evaluated the effectiveness of CDO1 and CELF4 methylation in predicting cancer risk.
• Identifying reliable predictors in endometrial cancer can lead to more targeted prevention and treatment strategies.